In conclusion, this study sheds further light on the dependency of different categories of AML on the level of the MYB transcription factor, demonstrating that, as we had previously described in the case of leukaemias driven by CEBPA mutations [17], there can be vastly different responses to a reduction in MYB levels. The gene discussed is CEBPA; the disease is acute myeloid leukemia.